UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 1-8036 WEST PHARMACEUTICAL SERVICES, INC. (Exact name of registrant as specified in its charter) Pennsylvania 23-1210010 (State or other ...

West Pharmaceutical Services, Inc. (NYSE:WST) Q4 2023 Earnings Conference Call February 15, 2024 9:00 AM ET Corporate Participants Quintin Lai - Vice President, Strategy and Investor Relations Eric Green - Chair, President and Chief Executive Officer Bernard Birkett - Senior VP and Chief Financial and Operations Officer Conference Call Participants David Windley - Jefferies Paul Knight - KeyBanc Capital Markets Jacob Johnson - Stephens Derik De Bruin - Bank of America Matt Larew - William Blair John Sourbee ...

Fourth-Quarter 2023 and Full Year Results WST Q4/FY 2023 Earnings 1 | --- | |-------------------------------------------------------------------------------| | Quarter Overall Net Sales $732.0M \| 3.3% | | | | Diluted Earnings Per Share: $1.83 Adjusted Diluted Earnings Per Share: $1.83 | "We had strong 2023 base organic sales growth, excluding the headwinds from lower pandemic- related sales, led by high-value product (HVP) components and devices and contract manufacturing. Our continued investments in both ...

For the quarterly period ended September 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 1-8036 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 WEST PHARMACEUTICAL SERVICES, INC. (Exact name of registrant as specified in its charter) Pennsylvania 23-1210010 (State ...

Third-Quarter 2023 WST Q3 2023 Earnings 1 Third Quarter Overall Net Sales $747.4M | 8.8% Diluted Earnings Per Share: $2.14 Adjusted Diluted Earnings Per Share: $2.16 "We had a solid quarter of organic net sales growth, driven by our Proprietary Products' high-value product (HVP) and strong Contract Manufacturing components. We are observing a slowdown in restocking trends by large Pharma and Generic customers, which is reflected in our revised guidance. As we look to the fourth-quarter 2023, we anticipate d ...

West Pharmaceutical Services, Inc. (NYSE:WST) Q3 2023 Earnings Conference Call October 26, 2023 9:00 AM ET Company Participants Quintin Lai - Vice President of Investor Relations Eric Green - President & Chief Executive Officer Conference Call Participants Paul Knight - KeyBanc Capital Markets Larry Solow - CJS Securities Jacob Johnson - Stephens John Sourbeer - UBS Matt Larew - William Blair David Windley - Jefferies Justin Bowers - Deutsche Bank Derik De Bruin - Bank of America Operator Good day, and than ...

West Pharmaceutical Services, Inc. (NYSE:WST) Q2 2023 Earnings Conference Call July 27, 2023 9:00 AM ET Company Participants Quintin Lai - Vice President of Investor Relations Eric Green - President & Chief Executive Officer Bernard Birkett - Senior Vice President and Chief Financial & Operations Officer Conference Call Participants Larry Solow - CJS Jacob Johnson - Stephens Paul Knight - KeyBanc Derik De Bruin - Bank of America Matthew Larew - William Blair David Windley - Jefferies John Sourbeer - UBS Jus ...

Second-Quarter 2023 WST Q2 2023 Earnings 1 | --- | --- | |-------------------------------------------------------------------------------|-------| | Second Quarter Overall Net Sales $753.8M \| 2.3% | | | | | | Diluted Earnings Per Share: $2.06 Adjusted Diluted Earnings Per Share: $2.11 | | "We had a solid first-half of 2023, and with the momentum of our high-value product capacity expansion projects, we are well positioned for an even better second-half of the year. While COVID-19 related sales continued to ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 1-8036 WEST PHARMACEUTICAL SERVICES, INC. (Exact name of registrant as specified in its charter) Pennsylvania 23-1210010 (State or ot ...

West Pharmaceutical Services, Inc. (NYSE:WST) Q1 2023 Results Conference Call April 27, 2023 9:00 AM ET Company Participants Quintin Lai - IR Eric Green - CEO Bernard Birkett - CFO Conference Call Participants Larry Solow - CJS Securities Paul Knight - KeyBanc Capital Markets Matt Larew - William Blair Jacob Johnson - Stephens Derik De Bruin - Bank of America John Sourbeer - UBS Quintin Lai [Call Starts Abruptly] …conference call. We issued our financial results this morning, and the release has been posted ...